RxDoctor Payments Data

Alan Ekanem, MD

General Practice · Jacksonville, FLNPI 1104272335

Payments from drug & device makers

$792in general payments, 2019–2025

Across 45 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$157
  • Novartis$127
  • Novo Nordisk$114
  • Pacira Therapeutics, Inc.$94
  • Janssen Scientific Affairs, LLC$68
  • AstraZeneca$51
  • plus $180 from 8 others

What the payments were for

  • Food & beverage$792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$792 in reported general payments places this provider in the 75th percentile of 6,901 general practice providers in Florida.

See all general practice providers in Florida

Medicare billing

Part B allowed, 2024
$10,007
Medicare patients
20
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$106,960
EliquisApixaban92$106,546
OzempicSemaglutide81$103,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$46,141
EntrestoSacubitril/Valsartan22$37,605
JanuviaSitagliptin Phosphate39$36,979
XareltoRivaroxaban25$33,579
Tresiba Flextouch U-100Insulin Degludec33$25,107
MyrbetriqMirabegron12$16,268
Albuterol Sulfate HfaAlbuterol Sulfate162$7,793
Lantus SolostarInsulin Glargine,hum.Rec.Anlog63$5,730
Atorvastatin Calcium914$5,690
SymbicortBudesonide/Formoterol Fumarate16$5,615
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$4,226
Gabapentin330$3,878

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$114$103,19981 claims
GSKTrelegy Ellipta$157$46,14134 claims
NovartisEntresto$127$37,60522 claims
Johnson & JohnsonXarelto$13$33,57925 claims
AstraZenecaSymbicort$51$5,61516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,901 general practice providers in Florida.

Other general practice in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →